Inflammatory Bowel Disease

Barnes reviews 3-year VIVID-2 data showing durable remission, steroid-free control, and stable safety with mirikizumab in moderate-to-severe Crohn’s disease.

Catch up on disparities in IBD care, a potential new IBS drug, new insight on diet’s role in Crohn’s disease care, & more.

Lee explains how understanding immune responses years before Crohn’s symptoms may open the door to earlier intervention and prevention strategies.

Lee explains what is known about the preclinical phase of Crohn’s disease before symptoms appear and describes his study on the role immune dysregulation plays.

Sinha describes data supporting the safety and utility of a fasting-mimicking diet in Crohn’s disease and explores what may be next in this line of research.

Sinha explains current unmet needs in mild Crohn’s, the shortcomings of steroids for these patients, and what benefits a fasting-mimicking diet may offer.

Scott describes current unmet needs in IBD diagnosis and monitoring but points to the potential of a new GzmA activity-based optical assay.

Open-label RCT findings suggest a short-term, calorie-restrictive diet may be an effective intervention for mild and moderate Crohn’s disease.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Wingate reviews new Crohn’s and Colitis Foundation data on insurance barriers faced by young adults with IBD and offers practical insights for overcoming these challenges.

The Q4 recap for gastroenterology spotlights GI FDA news, new AGA guidelines, trial data for UC therapies, and more.

Catch up on IBD steroid exposure risk, intensive weight loss before colorectal cancer surgery, a new chronic idiopathic constipation treatment option, and more.

Crohn’s & Colitis Foundation survey findings show 18% of young adults with IBD work extra hours to afford care and > 1 in 3 are not confident navigating insurance.

An audio recap of the top 5 stories in healthcare news from the week of 12/28-1/3.

The gastroenterology year in review covers FDA approvals, IBD breakthroughs, IL-23 therapies, new guidelines, and advances in GI care.

Study findings highlight the prevalence of steroid use in IBD care and identify key subgroups at higher risk of exposure.

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Catch up on GI FDA news, new American Gastroenterological Association Crohn’s disease guidelines, and more gastroenterology updates from November.

State- and local-level disparities in the availability of gastroenterologist care disproportionately affect patients with IBD and populations living in rural and high-poverty areas.

The living guideline incorporates new medications and the latest data to make recommendations for moderate-to-severely active CD care.

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Afzali details GALAXI post hoc findings on guselkumab in Crohn’s disease.

Check out the latest GI FDA news, new trial data in IBD, headlines from ACG 2025, and more.

Keefer emphasizes the importance of treatment satisfaction and health-related quality of life in IBD and reviews findings from ASPIRE-CD.